Significance of Pembrolizumab in Head and Neck Cancer
Tanguy Seiwert, MD, assistant professor of medicine, associate leader, Head and Neck Cancer Program, University of Chicago, discusses the significance of pembrolizumab in head and neck cancer.
Seiwert believes this study presents a new class of active agents for head and neck cancer, and he and his colleagues hope to eventually prolong survival. Pembrolizumab is the first active therapy since cetuximab, so Seiwert and his colleagues have high hopes for future trials.
Going forward, Seiwert and his team have many questions to answer. They do not yet know how survival will be impacted, or whether to add a biomarker.
Tanguy Seiwert, MD, assistant professor of medicine, associate leader, Head and Neck Cancer Program, University of Chicago, discusses the significance of pembrolizumab in head and neck cancer.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
